SHR-1209 Placebo

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Mixed HyperlipemiaPrimary Hypercholesterolemia

Phase 3

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

CompletedNCT04844125

Jiangsu HengRui Medicine Co., Ltd.Primary Hypercholesterolemia

Start: 2021-04-14End: 2022-08-12Updated: 2023-04-25

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

CompletedNCT04849000

Jiangsu HengRui Medicine Co., Ltd.Mixed Hyperlipemia, Primary Hypercholesterolemia

Start: 2021-04-23End: 2023-01-13Updated: 2023-05-19

Related Papers

Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.

2025-10-01

Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia.

2025-06-301 citations